For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Tafamidis meglumine represents a genuine advancement . These groundbreaking therapies preserve the transthyretin protein, slowing its damaging build-up and alleviating the burden of the disease . Patients are now reporting po